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Background: The aim of this study was to evaluate the antibiotic susceptibility of Group A streptococcus (GAS) to antibiotics usually 
used in Iran for treatment of GAS pharyngitis in children.
Materials and Methods: From 2011 to 2013, children 3-15 years of age with acute tonsillopharyngitis who attended Mofid Children’s 
Hospital clinics and emergency ward and did not meet the exclusion criteria were enrolled in a prospective study in a sequential 
manner. The isolates strains from throat culture were identified as GAS by colony morphology, gram staining, beta hemolysis on 
blood agar, sensitivity to bacitracin, a positive pyrrolidonyl aminopeptidase (PYR) test result, and the presence of Lancefield A antigen 
determined by agglutination test. Antimicrobial susceptibility was identified by both disk diffusion and broth dilution methods.
Results: From 200 children enrolled in this study, 59 (30%) cases were culture positive for GAS. All isolates were sensitive to penicil-
lin G. The prevalence of erythromycin, azithromycin, and clarithromycin resistance by broth dilution method was 33.9%, 57.6%, and 
33.9%, respectively. Surprisingly, 8.4% of GAS strains were resistant to rifampin. In this study, 13.5% and 32.2% of the strains were 
resistant to clindamycin and ofloxacin, respectively.
Conclusion: The high rate of resistance of GAS to some antibiotics in this study should warn physicians, especially in Iran, to 
use antibiotics restrictedly and logically to prevent the rising of resistance rates in future. It also seems that continuous local sur-
veillance is necessary to achieve the best therapeutic option for GAS treatment.
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Introduction
Group A streptococcus (GAS), or Streptococcus pyogenes, is 
a facultative, Gram-positive coccus which causes a wide range 
of diseases in humans, from mild to life-threatening ones, 
such as pharyngitis, scarlet fever, tonsillitis, cellulitis, impetigo, 
erysipelas, proctitis, vulvovaginitis, pneumonia, endocarditis, 
meningitis, sepsis, necrotizing fasciitis, and myonecrosis [1-6].
GAS is the most common cause of bacterial pharyngitis in 
children [7]. Antibiotic resistance to this organism has been 
changing in recent years, mostly due to inappropriate usage of 
wide spectrum antibiotics [8]. The frequency of resistance of 
this organism to antibiotics and the number of drugs to which 
they are resistant have been increasing worldwide [9]. Cur-
rently, penicillin is the drug of choice for GAS pharyngitis 
treatment, and penicillin resistance to GAS has not been re-
ported yet [5, 8]. However, the prevalence of resistance to oth-
er antibacterial agents such as macrolides has been increasing 
[3, 4, 7, 10]. The antibiotic resistance rate to GAS is related to 
geographic and epidemiologic factors and the time of investi-
gation.
Continuous local surveillance is recommended to observe 
changes in the antimicrobial susceptibility profile of GAS in 
order to guide physicians to choose appropriate antibiotics.
There are scanty data on epidemiology and antibiotic resis-
tance of GAS in Iranian children. The current resistance pat-
tern of GAS in Iran is unknown; therefore, this study was con-
ducted to evaluate the antibiotic susceptibility of GAS to the 




In this prospective study, children 3-15 years of age with 
acute tonsillopharyngitis who attended.
Mofid Children’s Hospital emergency ward in Tehran, Iran 
were enrolled in a sequential manner from 2010-2013. The 
study was approved by the ethics review committee for clini-
cal research, Pediatric Infectious Research Center (PIRC). In-
formed consent was received from children’s guardians before 
enrollment.
Exclusion criteria were pharyngitis with at least one of the 
following signs and symptoms: conjunctivitis, coryza, promi-
nent cough, vesicular or ulcerative stomatitis, and hoarseness 
or aphonia. Throat culture was carried out in 200 children.
2. Sample collection, transport, and culture
A throat sample was obtained with a Dacron swab from the 
patients by a physician and was transported to the Pediatric 
Infectious Research Center in the thioglycolate transport me-
dia within 2 hours. Each sample was cultured on trypticase 
soy blood agar with 5% sheep blood, incubated overnight at C 
under 5% CO2 effect, and tested for the pressure of GAS by the 
formation of distinct zones of beta hemolysis around colonies. 
The isolated strains were identified as GAS by colony mor-
phology, gram staining, beta hemolysis on blood agar, sensi-
tivity to bacitracin (inhibition screening test using 0.04-Ubaci-
tracin disk), a positive pyrrolidonyl arylamidase (PYR) test 
result, and the presence of Lancefield A antigen determined 
by agglutination test.
3. Antibiotic susceptibility testing
Antimicrobial susceptibility was first identified by disk diffu-
sion method on Muller-Hinton agar supplemented with 5% 
defibrinated sheep blood using the disk of commonly used 
antibiotics in Iran and in accordance with Clinical and Labo-
ratory Standards Institute (CLSI 2012) guideline [11].
The antibiotics used were erythromycin (15 μg), penicil-
lin (1 μg), azithromycin (15 μg), clarithromycin (15 μg), 
ofloxacin (5 μg), clindamycin (2 μg), rifampin (5 μg), ceftriax-
one, and cefixime.
Cefixime is one of the most commonly used antibiotics for 
upper respiratory tract infection treatment in Iran, but in vitro 
susceptibility of Streptococcus pyogenes to this antibiotic is not 
included in the CSLI 2012 guideline; therefore, another refer-
ence for determining the rate of susceptibility was used [11, 12].
Susceptibility of the GAS strains to the described antibiotics 
was also checked by the broth dilution method according to 
the CLSI, 2012 guideline recommendation. Briefly susceptibil-
ity testing was performed by broth microdilution procedure 
using dried plates reconstituted with Mueller–Hinton broth 
with 5% lysed horse blood. The inocula were 5 × 105 CFU/mL. 
The microdilution trays were incubated in ambient air at 35°C 
for 24 hours. Minimum inhibitory concentration (MIC) was 
determined after 24 hours of incubation and was defined as 
the lowest concentration that yielded no visible growth. Strep-
tococcus pneumoniae ATCC 49619 was included as a control 
strain.
4. Statistical analysis
Frequency of categorical variables including susceptible 
and resistant strains, age groups, and sign and symptoms were 
reported as numbers and percentages.
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Results
From 200 children 3-15 years of age with acute tonsillophar-
yngitis enrolled in this study, 59 (30%) cases were culture pos-
itive for GAS, 33 (55.9%) of which were male. The age distribu-
tion of the patients is shown in Table 1. The incidence of GAS 
pharyngitis was most prevalent in the 3-5 years age group. The 
comparison of antibiotic susceptibility tests results performed 
by disc diffusion and broth dilution methods is shown in Ta-
ble 2. All of the isolates were sensitive to penicillin. The preva-
lence of erythromycin, azithromycin, and clarithromycin re-
sistance by broth dilution method was 33.9%, 57.6%, and 
33.9%, respectively. Surprisingly, 8.4% of GAS strains were re-
sistant to rifampin. The prevalence of signs and symptoms are 
shown in Table 3.
All of the cases had fever. The most prevalent symptom after 
fever was sore throat. The most prevalent sign of streptococcal 
pharyngitis was Pharyngeal erythema.
Discussion
Although there are several therapeutic options for GAS 
pharyngitis, the most acceptable recommendation is single 
dose intramuscular benzathine penicillin in Iran because 
penicillin is the drug of choice for the treatment of GAS phar-
yngitis, and no GAS resistance to this antibiotic has been re-
ported yet throughout the world [5]. In addition, the compli-
ance of Iranian parents for ten days oral therapy is usually low.
On the other hand, there are some families that do not ac-
cept injection, or patients with immediate- type hypersensi-
tivity to penicillin that compel pediatricians to use other ther-
apeutic options such as macrolides, oral beta lactams, 
clindamycin, or oral cephalosporins [5,13]. So it is very im-
portant for all the physicians to be aware of local antimicrobi-
al susceptibility patterns to select appropriate alternative 
treatment options.
In our study, all the GAS strains were susceptible to penicil-
lin, so this antibiotic remains the drug of choice for GAS phar-
yngitis.
Surprisingly, 8.4% of GAS strains were resistant to rifampin 
by broth dilution method, and 5% of the strains had interme-
diate sensitivity to this antibiotic. In other studies from Roma-
nia in 2011, the USA in 2003, and Greece in 2009, all of the 
GAS strains were susceptible to rifampin [14, 15]. Epidemio-
logically, most of the provinces of Iran are endemic for tuber-
culosis, so it seems that rifampin usage as one the main agents 
of tuberculosis treatment might be a cause of increasing resis-
tance to rifampin, and this is an alarm for physicians in areas 
endemic for tuberculosis to be aware and use the anti-tuber-
culosis antibiotics cautiously. In addition, rifampin might be 
Table 2. Antimicrobial resistance pattern for GAS isolated from the pharynx of the patients by disk diffusion and broth dilution method (n = 59) 
Disk diffusion Broth dilution
S (n, %) I (n, %) R (n, %) S (n, %) I (n, %) R (n, %)
Penicillin 59 (100)   0 (0.0)   0 (0) 59 (100)   0 (0.0)   0 (0.0)
Erythromycin 29 (49.1)   8 (13.5) 22 (37.2) 35 (59.3)   4 (6.7) 20 (33.9)
Azithromycin 26 (44.0)   3 (5.0) 30 (50.8) 21 (35.5)   4 (6.7) 34 (57.6)
Clarythromycin 26 (44.0) 11 (18.6) 22 (37.2) 32 (54.3)   7 (11.8) 20 (33.9)
Ofloxacin 35 (59.3)   5 (8.4) 19 (32.2) 36 (61.0)   4 (6.7) 19 (32.2)
Clindamycin 50 (84.7)   0 (0.0)   9 (15.2) 49 (83.0)   2 (3.3)   8 (13.5)
Rifampicin 44 (74.6)   6 (10.2)   9 (15.2) 51 (86.4)   3 (5.0)   5 (8.4)
Ceftriaxona - - - 49 (83.0)   3 (5.0)   7 (11.8)
Cefixima, b - - - 35 (59.3) 14 (33.7) 10 (16.9)
GAS, group A streptococcus; S, sensitive; I, intermediate; R, resistant.
aAntibiotic susceptibility of GAS is not defined by CLSI for  disk diffusion method.
bAntibiotic susceptibility of GAS is not defined by CLSI for both disk diffusion and broth dilution method.
Table 1. Prevalence of streptococcal pharyngitis according to age groups 
(n = 200)




Positive for GAS 
pharyngitis
3-5 108 (54%) 36 (33.3%)
6-8   57 (28.5%) 16 (28%)
9-11   30 (15%)   5 (16.6%)
12-15     5 (2.5%)   2 (40%)
Total 200 (100%) 59 (29.5%)
GAS, Group A streptococcus.
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used in the treatment regimen of some infections caused by 
multi-resistant microorganisms, such as acinetobacter spp. 
and MRSA. The increasing rate of these multi drug- resistant 
microorganisms in recent years might be another cause of in-
creasing consumption and resistance to rifampin.
Macrolides have been widely used for the treatment of GAS 
pharyngitis, and it seems that high resistance to the macro-
lides in recent years is related to this over usage.
In our study, 33.9%, 57.6%, and 33.9% of the GAS strains 
were resistant to erythromycin, azithromycin, and clarithro-
mycin, respectively.
Other studies confirm the increasing rate of resistance to 
macrolides in most parts of the world [4, 16]. An increasing 
trend toward erythromycin resistance was reported from Tai-
wan, and then decreased once the use of this antibiotic was 
reduced [17]. The resistance rate to erythromycin decreased 
from 53.1% in 1998 and 2000 to 14.6% in 2002 and 2004, and 
finally to 10.7% in 2006-2010 [17].
Currently, treatment of GAS pharyngitis with macrolides is 
absolutely discouraged in Iran. The results of a surveillance 
study in Iran from 1995-1997 showed 0.2% resistance to eryth-
romycin [18]. After nearly 15 years, the resistance rate has 
reached 33.9% and 57.6% resistance to erythromycin and azi-
thromycin, respectively. These findings might be the result of 
inappropriate use of these antibiotics in recent years in Iran.
Surprisingly the resistance to azithromycin was more than 
the two other macrolides. Azithromycin is one of the antibiot-
ics in which general practitioners and pediatricians are very 
interested in Iran. Its low cost, availability and short course of 
therapy have made it a first choice for many related pediatric 
infections. Clarithromycin is more expensive and less popular 
for usage among general practitioners in Iran. Longer course 
of therapy (10 vs. 5 days) and more side effects have made 
Erythromycin loss its priority after introduction of the azithro-
mycin. So it seems that the increased resistance of azithromy-
cin in comparison of the two other macrolides is related to its 
more consumption in Iran.
In this study, 13.5% of strains were resistant to clindamycin, 
which is similar to the result of a study from Romania in 2011 
in which 15% of the strains were resistant to clindamycin [15]. 
This rate of resistance should warn physicians to use this anti-
biotic restrictedly and logically to prevent the rising resistance 
rate in the future. A study from Korea showed 32.5% resistance 
of GAS to clindamycin [2]. Nevertheless there are some re-
ports showing very low resistance to clindamycin from other 
countries [14, 19]. This might be related to difference in the 
rate of resistance genotypes and phenotypes (e.g. cMLSB and 
iMLSB) or policies of antibiotic consumption among different 
parts of the world. 
The resistance rate of our GAS strains to ofloxacin, the only 
fluoroquinolone that was evaluated in our study, was 32.5%. 
In general, older fluoroquinolones (e.g., ciprofloxacin) have 
limited activity against GAS pharyngitis and should not be 
used to treat GAS pharyngitis [20]. Newer fluoroquinolones 
(e.g., levofloxacin and moxifloxacin) are active in vitro against 
GAS, but they are expensive, have an unnecessarily broad 
spectrum of activity, and therefore not recommended for rou-
tine treatment of GAS pharyngitis [20].
In 2003, a study from the USA showed 0.05% resistance of 
GAS to levofloxacin [19]. On the other hand, a study from Bel-
gium identified an increase in fluoroquinolones non-suscepti-
bility from 4.3% (2008) to 10.9% (2009) to 21.6% in 2010 [21].
Although fluoroquinolones are used restrictedly in the pedi-
atric age group, it seems that inappropriate use of this catego-
ry of antibiotics in domestic animals, veterinary medicine, in-
dustries, and also in adults has raised the GAS resistance to 
these agents in recent years in our region.
Although some studies from 2002 to 2012 with no GAS resis-
tance to cefteriaxon exist, 11.8% of the GAS stains in the cur-
rent study were resistant to this antibiotic, which might again 
be the result of its over-usage in our country [14]. The relation-
ship between antibiotic usage and resistance is strongly sup-
ported by data from this study. It seems that countries with 
the highest per capita antibiotic consumption have the high-
est resistance [9].
The signs and symptoms of GAS pharyngitis overlap exten-
sively with other infectious causes, particularly viral agents, 
making a diagnosis based solely on clinical findings difficult 
[5, 13].
Although there are several scoring systems to raise the prob-
Table 3. Prevalence of signs and symptoms in the patients with tonsillo-
pharyngitis in this study
GAS positive (n=59)
Fever 59 (100%)
Pharyngeal erythema 56 (94.9%)
Sore throat  55 (93.2%)
Pharyngeal exudates 46 (77.9%)
Headache 14 (23.7%)
Abdominal pain 10 (16.9%)
Cervical lymphadenopathy 12 (20.3%)
Vomiting   7 (11.8%)
Values are presented as n (%).
GAS, group A streptococcus.
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ability of streptococcal pharyngitis in children, none of them 
could definitely differentiate streptococcal from non-strepto-
coccal ones.
In this study, despite usage of the exclusion criteria, only 
one-third of the enrolled cases were culture positive. One of 
the most important reasons for this problem is the liberal use 
of antibiotics in Iran, which affects the rate of positive cultures. 
In addition, our study was based on culture result, and rapid 
antigen test or serologic study for detecting GAS infection was 
not performed; therefore, the GAS positive-culture negative 
cases could not be determined.
According to 2012 Infectious Diseases Society of America 
guideline for the diagnosis and management of group A strep-
tococcal pharyngitis, diagnostic studies for GAS pharyngitis 
are not indicated for children <3 years. Therefore, we conduct-
ed our study for children 3-15 years old particularly because 
streptococcal pharyngitis is most prevalent in 5-15 years old 
cases [20].
The most prevalent symptoms of streptococcal pharyngitis 
are the sudden onset of fever greater than 38°C and sore throat 
[5, 13]. Cervical lymphadenopathy, pharyngeal and/or tonsil-
lar inflammation, or exudates are common signs [5, 13]. Pala-
tal petechiae and scarlatiniform rash are highly specific, but 
uncommon [13]. Some nonspecific symptoms such as head-
ache, vomiting, and abdominal pain may also be noted [13]. 
In our study, the most prevalent symptoms and signs were fe-
ver, sore throat, and pharyngeal erythema and exudate, re-
spectively. In our and most other studies, fever is the most 
constant symptom of streptococcal pharyngitis, so it seems 
that absence of fever could generally help to rule out GAS 
pharyngitis.
In conclusion, it seems that the high rate of GAS resistance 
to some antibiotics in this study should warn physicians to 
use the antibiotics restrictedly and logically to prevent the ris-
ing of resistance rates in the future. Continuous local surveil-
lance is also necessary to achieve the best therapeutic option 
for GAS treatment.
Although the number of isolates in this study was not suffi-
cient to make any epidemiological conclusions, the high resis-
tance to some antibiotics could render these data useful for 
future decisions to develop a therapeutic streptococcal guide-
line in Iran.
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